Interv Akut Kardiol. 2018;17(2):123-125 | DOI: 10.36290/kar.2018.048

Update of antithrombotic treatment

Petr Kala
Interní kardiologická klinika FN a LF MU, Brno

Rapid development of antithrombotic treatment has significantly improved the quality of care of patients with ischemic heartdisease as well as contributed to the development of cardiovascular medicine and interventional cardiology, in particular. In thispaper, individualized therapy based on risk stratifications, treatment strategy, algorithms for dual antiplatelet therapy and itscombination with oral anticoagulation will be discussed.

Keywords: antithrombotic treatment, PCI, oral anticoagulation, dual antiplatelet therapy

Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kala P. Update of antithrombotic treatment. Interv Akut Kardiol. 2018;17(2):123-125. doi: 10.36290/kar.2018.048.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Schömig A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 1996; 334: 1084-1089. Go to original source... Go to PubMed...
    2. Costa F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet Lond. Engl. 2017; 389: 1025-1034. Go to original source... Go to PubMed...
    3. Yeh RW, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016; 315: 1735-1749. Go to original source... Go to PubMed...
    4. Valgimigli M, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSThe Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2018; 39: 213-260. Go to original source... Go to PubMed...
    5. Baber U, et al. Coronary Thrombosis and major bleeding after pci with drug-eluting stents: Risk Scores From PARIS. J. Am. Coll. Cardiol. 2016; 67: 2224-2234. Go to original source... Go to PubMed...
    6. Abu-Assi E, et al. Assessing the performance of the PRECISE-DAPT and PARIS risk scores for predicting one-year out-of-hospital bleeding in acute coronary syndrome patients. EuroIntervention J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. 2018; 13: 1914-1922. Go to original source... Go to PubMed...
    7. Montalescot G, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N. Engl. J. Med. 2014; 371: 1016-1027. Go to original source... Go to PubMed...
    8. Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009; 361: 1045-1057. Go to original source... Go to PubMed...
    9. Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2007; 357: 2001-2015. Go to original source... Go to PubMed...
    10. Sabatine MS, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 2005; 352: 1179-1189. Go to original source...
    11. Montalescot G, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N. Engl. J. Med. 2013; 369: 999-1010. Go to original source... Go to PubMed...
    12. Steg PG, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet Lond. Engl. 2013; 382: 1981-1992. Go to original source...
    13. Angiolillo DJ, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J. Thromb. Thrombolysis 2012; 34: 44-55. Go to original source... Go to PubMed...
    14. Dewilde WJM, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet Lond. Engl. 2013; 381: 1107-1115. Go to original source... Go to PubMed...
    15. Dewilde WJM, et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. 2015; 11: 381-390. Go to original source... Go to PubMed...
    16. Gibson CM, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med. 2016; 375: 2423-2434. Go to original source... Go to PubMed...
    17. Varenne O, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. The Lancet 2018; 391: 41-50. Go to original source... Go to PubMed...
    18. Urban P, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N. Engl. J. Med. 2015; 373: 2038-2047. Go to original source... Go to PubMed...
    19. Naber CK, et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. Eur. Heart J. 2017; 38: 961-969. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.